Welcome to our dedicated page for Cooper news (Ticker: COO), a resource for investors and traders seeking the latest updates and insights on Cooper stock.
The Cooper Companies, Inc. reports developments for a global medical device business organized around CooperVision and CooperSurgical. CooperVision news centers on soft contact lenses, specialty lens designs, myopia management products such as MiSight® 1 day, MyDay® contact lenses, practitioner support, and sustainability initiatives tied to lens materials, packaging, manufacturing, and plastic footprint programs.
CooperCompanies news also covers quarterly financial results, conference participation, board appointments, and governance matters. CooperSurgical provides fertility and women’s healthcare products, while companywide updates describe operating performance, capital priorities, and corporate developments across its medical device portfolio.
CooperCompanies (NYSE: COO) has declared a semi-annual dividend of 3 cents per share, payable on August 7, 2020, to stockholders of record on July 23, 2020. This decision aligns with the company's commitment to pay annual dividends as approved by its board of directors. CooperCompanies operates through two key divisions: CooperVision, focused on vision care products, and CooperSurgical, dedicated to women's health and fertility solutions, with products available in over 100 countries.
CooperCompanies announced the appointment of Holly Sheffield as President of CooperSurgical, effective July 13, 2020, following the retirement of Robert Auerbach. Auerbach will remain in an advisory role until February 1, 2021. Sheffield has been with Cooper since June 2018 as Executive VP and Chief Strategy Officer, previously serving at UBS Securities LLC. CEO Albert White expressed confidence in Sheffield's leadership capabilities, highlighting a seamless transition ahead for the company.
CooperCompanies (NYSE: COO) reported a 20% decline in revenue for Q2 2020, totaling $524.9 million, impacted by the COVID-19 pandemic. CooperVision's revenue decreased 17% to $402.2 million, while CooperSurgical saw a 28% drop to $122.7 million. GAAP diluted EPS fell 91% to $0.23, while non-GAAP EPS was $1.51, down 48%. Operating margins dropped significantly to 5% from 22% year-over-year. The company has suspended its fiscal year 2020 guidance due to uncertainty.
CooperCompanies (NYSE: COO) plans to release its second quarter 2020 financial results on June 4, 2020, at 4:15 PM ET. A conference call will follow at 5:00 PM ET to discuss results and corporate developments. Investors can join via dial-in or a webcast available on the CooperCompanies website. A recording of the call will be accessible from June 4 at 8:00 PM ET until June 11, 2020. Cooper operates through CooperVision and CooperSurgical, focusing on vision care and women's health.